Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rd vs Rd-R in Elderly Unfit Multiple Myeloma
NCT02215980Phase 3Completed
- Sponsor
- Fondazione EMN Italy
- Start
- Jul 2014
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoint: Event-Free Survival at 3 years. Started Jul 2014; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02215980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215980.